Leonardo Ferreira, Ph.D., left, and graduate student Russell Cochrane envision CAR Tregs being useful in cancer, type 1 diabetes and organ transplants. A new paper from MUSC Hollings Cancer Center ...
Oral presentations highlight first-in-human data for TRX103 and novel CAR-Tr1 Treg therapy TRX319. Data underscore potential ...
London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today ...
CAR-T cell therapy works well in blood cancers, but many patients still become resistant. A key reason is the presence of CAR ...
London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), today announced that it has initiated a Phase 1/2 basket clinical study evaluating its autologous CAR-Treg therapy, QEL-005, in patients ...
U.K. developer Quell Therapeutics hired eXmoor Pharma to make supplies of its pipeline of novel immunosuppressive cell therapies—called CAR-Tregs—at its new cell and gene therapy facility. Quell ...
London, UK– June 4, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces ...
TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and ...
Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate development New CAR-Treg cell therapy ...
Quell CAR-Tregs engrafted in the liver tissue where HLA-A2 is expressed with 10-20% enrichment of the Treg pool vs. <1% in the circulation. Quell CAR-Treg engraftment within the liver was focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results